<DOC>
	<DOCNO>NCT00553358</DOCNO>
	<brief_summary>This randomise , open label multicenter Phase III study compare efficacy neoadjuvant lapatinib plus paclitaxel , versus trastuzumab plus paclitaxel , versus concomitant lapatinib trastuzumab plus paclitaxel give neoadjuvant treatment HER2/ErbB2 over-expressing and/or amplify primary breast cancer . Patients randomise receive either : lapatinib 1500 mg daily , trastuzumab 4 mg/kg intravenous ( IV ) load follow 2 mg/kg IV weekly , lapatinib 1000 mg daily trastuzumab 4 mg/kg IV load follow 2 mg/kg IV weekly total 6 week . After biological window , patient monotherapy arm continue target therapy plus weekly paclitaxel 80 mg/m^2 12 week , definitive surgery . In combination arm , patient receive lapatinib 750 mg daily combination trastuzumab 2 mg/kg IV plus weekly paclitaxel 80mg/m^2 IV 12 week , definitive surgery . After surgery , patient receive three course adjuvant chemotherapy 5-Fluorouracil Epirubicin Cyclophosphamide ( FEC ) follow targeted therapy biological window neoadjuvant set 34 week ( combination arm , lapatinib dose 1000 mg daily combination trastuzumab ) . The planned total duration anti-HER2 therapy one year .</brief_summary>
	<brief_title>Neo ALTTO ( Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation ) Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female gender ; Age ≥18 year ; Performance Status Eastern Cooperative Oncology Group ( ECOG ) 01 Histologically confirm invasive breast cancer : Primary tumour great 2 cm diameter , measure clinical examination mammography echography , Any N , No evidence metastasis ( M0 ) ( isolated supraclavicular node involvement allow ) ; Over expression and/or amplification HER2 invasive component primary tumour [ Wolff et al 2006 ] confirm certified laboratory prior randomisation Known hormone receptor status . Haematopoietic status : Absolute neutrophil count ≥ 1,5 x 10^9/L , Platelet count ≥ 100 x 10^9/L , Hemoglobin least 9 g/dl , Hepatic status : Serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) . In case know Gilbert 's syndrome , high serum total bilirubin ( &lt; 2 x ULN ) allow , Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) ≤ 2.5 time ULN , Alkaline phosphatase ≤ 2.5 time ULN , Renal status : Creatinine ≤ 2.0 mg/dL , Cardiovascular : Baseline leave ventricular ejection fraction ( LVEF ) ³ 50 % measure echocardiography ( ECHO ) Multiple Gate Acquisition ( MUGA ) scan , Negative serum pregnancy test , within 2weeks ( preferably 7 day ) prior randomization ( For woman childbearing potential ) Fertile patient must use effective contraception ( barrier method condom , diaphragm also conjunction spermicidal jelly , total abstinence . Oral , injectable , implant hormonal contraceptive allow ) Signed informed consent form ( ICF ) Patient accepts make available tumour sample submission central laboratory conduct translational study part protocol Received prior treatment primary invasive breast cancer ; Previous ( less 10 year ) current history malignant neoplasm , except curatively treat : Basal squamous cell carcinoma skin ; Carcinoma situ cervix . Patients prior malignancy diagnose 10 year prior randomisation may enter study . Patients must curatively treat surgery alone . Radiation therapy systemic therapy ( chemotherapy endocrine ) NOT permit . Prior diagnosis breast cancer melanoma exclude . Diagnosis inflammatory breast cancer ; Bilateral cancer ; This criterion delete protocol Version 1 . Patients multifocal cancer longer exclude . Known history uncontrolled symptomatic angina , clinically significant arrhythmia , congestive heart failure , transmural myocardial infarction , uncontrolled hypertension ( ≥180/110 ) , unstable diabetes mellitus , dyspnoea rest , chronic therapy oxygen ; Concurrent disease condition would make subject inappropriate study participation serious medical disorder would interfere subject 's safety ; Unresolved unstable , serious adverse event prior administration another investigational drug ; Active uncontrolled infection ; Dementia , alter mental status , psychiatric condition would prevent understand render ICF ; Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel . Subjects ulcerative colitis also exclude ; Concurrent neoadjuvant cancer therapy ( chemotherapy , radiation therapy , immunotherapy , biologic therapy trial therapy ) ; Concurrent treatment investigational agent participation another therapeutic clinical trial ; Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate trastuzumab lapatinib excipients ; Pregnant lactate woman ; Concomitant use CYP3A4 inhibitor inducer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Lapatinib</keyword>
	<keyword>ErbB2+</keyword>
	<keyword>Early Breast Cancer</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>